Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

AIMS : Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism and reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur Heart J
Main Authors: Gaudet, Daniel, Karwatowska-Prokopczuk, Ewa, Baum, Seth J, Hurh, Eunju, Kingsbury, Joyce, Bartlett, Victoria J, Figueroa, Amparo L, Piscitelli, Philip, Singleton, Walter, Witztum, Joseph L, Geary, Richard S, Tsimikas, Sotirios, O'Dea, Louis St. L
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Fast Track Congress
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7750927/
https://ncbi.nlm.nih.gov/pubmed/32860031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa689
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados